Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Advanced High-grade Ovarian Cancer|Triple Negative Breast Cancer
Interventions: DRUG: Pamiparib
Sponsor: BeiGene